Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
REGN4461 - Mibavademab
Lacuna Pharma Pty Ltd
Monogenic obesity
1 trial -
REGN7508, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, Eliquis 2.5 mg film-coated tablets, SODIUM CHLORIDE, REGN7508
Lacuna Pharma Pty Ltd
Thromboembolic disease
1 trial -
RITUXIMAB, Capsule, hard, Calquence 100 mg hard capsules, BENDAMUSTINE
Lacuna Pharma Pty Ltd
Mantle Cell Lymphoma
1 trial -
Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.
Lacuna Pharma Pty Ltd
Immune Thrombocytopenia (ITP)
1 trial -
Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -
Lacuna Pharma Pty Ltd
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)
1 trial -
Soliris 300 mg concentrate for solution for infusion, Pozelimab, Cemdisiran, Ultomiris 300 mg/3 mL concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Paroxysmal nocturnal haemoglobinuria (PNH)
1 trial -
Solution for Injection, subcutaneous Use, IMCIVREE 10 mg/ml solution for injection
Lacuna Pharma Pty Ltd
Improper function of certain messenger materials in the body that control body weight and hunger in people
1 trial -
Sovateltide, Sovateltide matching placebo
Lacuna Pharma Pty Ltd
Acute cerebral ischemic stroke
1 trial -
Sterile normal saline (0.9% sodium chloride solution), ADX-324
Lacuna Pharma Pty Ltd
Hereditary Angioedema
1 trial -
Sunitinib AqVida 12,5 mg Hartkapseln, QINLOCK 50 mg tablets
Lacuna Pharma Pty Ltd
Patients with Advanced Gastrointestinal Stromal Tumors
1 trial -
T89 Placebo; capsules contain brown coated dripping pills., Nitroglycerin Orifarm 0,5 mg tabletes lietošanai zem mēles
Lacuna Pharma Pty Ltd
Stable Angina Pectoris
1 trial -
TASIMELTEON, HETLIOZ 20 mg hard capsules
Lacuna Pharma Pty Ltd
Non-24 Hour Sleep-Wake Disorder
1 trial -
TAXOL 6 mg/ml, concentrato per soluzione per infusione
Lacuna Pharma Pty Ltd
Recurrent or Metastatic HER2 Negative Breast Cancer
1 trial -
TOPOTECAN, TOPOTECAN, IRINOTECAN, TOPOTECAN, lurbinectedin, TOPOTECAN
Lacuna Pharma Pty Ltd
Small Cell Lung Cancer (SCLC)
1 trial -
Taldefgrobep, Placebo Solution for injection in pre-filled syringe, Taldefgrobep
Lacuna Pharma Pty Ltd
Spinal Muscular Atrophy
1 trial -
Temodal 100 mg hard capsules, Temodal 250 mg hard capsules, Placebo, 2-Hydroxyoleic acid sodium salt, Temodal 140 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 180 mg hard capsules
Lacuna Pharma Pty Ltd
Newly diagnosed primary glioblastoma multiforme (ndGBM)
1 trial -
Temomedac 20 mg hard capsules, Temomedac 5 mg hard capsules, Tirabrutinib, Temomedac 100 mg hard capsules, Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Relapsed/refractory primary central nervous system lymphoma
1 trial -
The placebo for NW-3509 drug product contains blended lactose monohydrate (29.50 mg/caps), microcrystalline cellulose (70.00 mg/caps), and magnesium stearate (0.50 mg/caps) filled into hard gelatin capsules.
Lacuna Pharma Pty Ltd
treatment-resistant schizophrenia (TRS)
1 trial -
The placebo has the same composition as the investigational medicinal product Clinitrat® (6.563+175,4+89,3+23,3) mg/sachet (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., CLINITRAT® (6.563+175,4+89,3+23,3) mg/sachet ή stick, Κόνις για πόσιμο διάλυμα
Lacuna Pharma Pty Ltd
Second line treatment for colonoscopy preparation
1 trial -
The placebo product is manufactured to visually match the corresponding FDY-5301 injection drug product. It is formulated to match a standard saline solution comprised of Sodium Chloride and Water for Injection.
Lacuna Pharma Pty Ltd
Anterior ST-Elevation Myocardial Infarction
1 trial -
Tildrakizumab Placebo Solution for Injection, TILDRAKIZUMAB
Lacuna Pharma Pty Ltd
Moderate to Severe Genital Psoriasis
1 trial -
Tildrakizumab matching placebo, Enbrel 25 mg powder for solution for injection, Tildrakizumab
Lacuna Pharma Pty Ltd
Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis
1 trial -
Tovorafenib, VINCRISIN 1 mg/ml solution injectable, 2 mg, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tovorafenib, VELBE 10 mg Trockensubstanz zur Injektionsbereitung, Vinblastin STADA 10 mg Pulver zur Herstellung einer Injektionslösung, cellcristin® 1 mg/ml Injektionslösung Wirkstoff: Vincristinsulfat, Vincristinesulfaat Teva 1 mg/ml, oplossing voor injectie, Vinblastinesulfaat 1 mg/ml PCH, oplossing voor injectie
Lacuna Pharma Pty Ltd
Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy
1 trial -
Tradipitant
Lacuna Pharma Pty Ltd
Idiopathic or diabetic gastroparesis with moderate to severe nausea.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources